| Dr Matthew Carlisle Hagen, MD, PHD | |
|
234 Goodman St, Cincinnati, OH 45219-2364 | |
| (513) 584-7284 | |
| (513) 584-3807 |
| Full Name | Dr Matthew Carlisle Hagen |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 19 Years |
| Location | 234 Goodman St, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447411251 | NPI | - | NPPES |
| 0051637 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 35097773 (Ohio) | Secondary |
| 207ZN0500X | Pathology - Neuropathology | 35 097773 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Cincinnati Medical Center, Llc | Cincinnati, OH | Hospital |
| West Chester Hospital | West chester, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Cincinnati Physicians Company Llc | 2264344480 | 1339 |
News Archive
Alexza Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010 and provided a business update. The net loss for the three and six months ended June 30, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $12.9 million and $26.3 million, respectively, compared to a net loss of $17.0 million and $23.9 million in the respective comparable periods in 2009. Alexza had consolidated cash, cash equivalents and marketable securities at June 30, 2010 of $41.7 million.
Older adults with more harmful than healthy bacteria in their gums are more likely to have evidence for amyloid beta-a key biomarker for Alzheimer's disease-in their cerebrospinal fluid (CSF), according to new research from NYU College of Dentistry and Weill Cornell Medicine.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.
In the first six months of 2016, doctors at the North Carolina Jaycee Burn Center at UNC Hospitals treated 10 inpatients with severe burns and facial fractures from e-cigarette explosions. Almost all of them required surgery, and one patient lost his eye when an e-cigarette exploded while he puffed on it.
New studies have uncovered the specific interventions and advances that have led to the success with these at-risk populations in the poorest countries.
› Verified 6 days ago
| Entity Name | University Of Cincinnati Physicians Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801840434 PECOS PAC ID: 2264344480 Enrollment ID: O20031105000123 |
News Archive
Alexza Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010 and provided a business update. The net loss for the three and six months ended June 30, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $12.9 million and $26.3 million, respectively, compared to a net loss of $17.0 million and $23.9 million in the respective comparable periods in 2009. Alexza had consolidated cash, cash equivalents and marketable securities at June 30, 2010 of $41.7 million.
Older adults with more harmful than healthy bacteria in their gums are more likely to have evidence for amyloid beta-a key biomarker for Alzheimer's disease-in their cerebrospinal fluid (CSF), according to new research from NYU College of Dentistry and Weill Cornell Medicine.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.
In the first six months of 2016, doctors at the North Carolina Jaycee Burn Center at UNC Hospitals treated 10 inpatients with severe burns and facial fractures from e-cigarette explosions. Almost all of them required surgery, and one patient lost his eye when an e-cigarette exploded while he puffed on it.
New studies have uncovered the specific interventions and advances that have led to the success with these at-risk populations in the poorest countries.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Carlisle Hagen, MD, PHD Po Box 636256 Central Credentialing, Cincinnati, OH 45263-6256 Ph: (513) 585-5507 | Dr Matthew Carlisle Hagen, MD, PHD 234 Goodman St, Cincinnati, OH 45219-2364 Ph: (513) 584-7284 |
News Archive
Alexza Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010 and provided a business update. The net loss for the three and six months ended June 30, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $12.9 million and $26.3 million, respectively, compared to a net loss of $17.0 million and $23.9 million in the respective comparable periods in 2009. Alexza had consolidated cash, cash equivalents and marketable securities at June 30, 2010 of $41.7 million.
Older adults with more harmful than healthy bacteria in their gums are more likely to have evidence for amyloid beta-a key biomarker for Alzheimer's disease-in their cerebrospinal fluid (CSF), according to new research from NYU College of Dentistry and Weill Cornell Medicine.
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.
In the first six months of 2016, doctors at the North Carolina Jaycee Burn Center at UNC Hospitals treated 10 inpatients with severe burns and facial fractures from e-cigarette explosions. Almost all of them required surgery, and one patient lost his eye when an e-cigarette exploded while he puffed on it.
New studies have uncovered the specific interventions and advances that have led to the success with these at-risk populations in the poorest countries.
› Verified 6 days ago
Bruce G Storrs, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-872-1400 | |
Mei Liang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Lab Medicine Building, Cincinnati, OH 45219 Phone: 513-584-3834 Fax: 513-558-2289 | |
Parsa Hodjat, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 3333 Burnet Ave., Ml 1035, Cincinnati, OH 45229 Phone: 513-636-4261 Fax: 513-636-3924 | |
Gregory Retzinger, MD Pathology Medicare: Medicare Enrolled Practice Location: 231 Albert Sabin Way, Department Of Pathology, Cincinnati, OH 45267 Phone: 513-558-4500 Fax: 513-558-2289 | |
Ila N Mehta Iii, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 375 Dixmyth Ave, Cincinnati, OH 45220 Phone: 513-624-4337 | |
Jiang Wang, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-584-1000 Fax: 513-584-3778 | |
Dani S Zander, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-584-7284 Fax: 513-584-3807 |